Animal health, big pharma's emerging markets play.
Given Imaging slides on abandoned buyout hopes.
Santarus continues to soar past investor expectations.
Big news for Johnson and Johnson's diabetes drug.
Three things for Eli Lilly investors to focus on.
The BRIC countries are considered a big area of future growth for pharma.
Just how far can AbbVie push its number 1 moneymaker?
Is there a fix for soaring health-care costs?
Nearly every Big Pharma company is looking for a slice of the diabetes market.
Express Scripts' future plans for growth.
Is all of the upside already baked into Medivation?
Here are 3 key things that could drive Medivation shares.
This Fool thinks Bausch & Lomb is on its own.
Four major themes from the year's biggest healthcare conference.
1 biotech that hasn't been receiving much attention lately
The new Abbott Labs, minus AbbVie, speaks for the first time.
A bear's take on the Dendreon conference presentation.
This pharmacy benefit management company's relatively small size can be a big asset.
The explosion is on the way for this struggling health-care industry.
Is the PBM industry headed for tough times?